Monday, April 22, 2024
HomeNews ReportsBharat Biotech announces Covaxin prices for state governments and private hospitals for Phase 3...

Bharat Biotech announces Covaxin prices for state governments and private hospitals for Phase 3 of Covid-19 vaccination program

Bharat Biotech said the prices that Covaxin is an inactivated and highly purified vaccine, which makes its manufacturing process expensive due to low yields

Bharat Biotech, the developer and manufacturer of Covid-19 vaccine Covaxinm, today announced the prices to be charged from state governments and the private sector in the third phase of the Covid-19 vaccination program in the country. The company has said that Covaxin price for the state governments will be ₹600, and the price for private hospitals will be ₹1200. The company has set the export price of the vaccine in the range of $15 to $20, which equals around ₹1120 to ₹1500 in Indian rupees.

Bharat Biotech has been supplying the vaccine to the union govt at ₹150 per dose, which is distributed free of charge by the govt of India. The company informed that it has reserved more than 50% of its capacity for central govt supply.

The company announced the prices as per the order issued by the Ministry of Health and Family Welfare on 19th April opening up the vaccination for anyone above 18 years of age. The govt had said that while the central govt will continue to vaccinate people above 45 years of age free of charge, state governments and private hospitals will be allowed the buy vaccines to vaccinate the adult population of the country. The ministry had asked the vaccine manufacturers to transparently declare the price they will charge from state govts and the open market before 1st May, from when the third phase will begin.

The govt order had said that manufacturers will sell 50% of their vaccine to the union govt, which will be used to vaccinate 45+ people all over the country, while the rest 50% will be sold to states and the open market.

Serum Institute of India, the manufacturer of the Covid-19 vaccine COVISHIELD developed by Oxford University-AstraZeneca, had announced the prices on 21st April. The company had set the state govt price at ₹400 and the private sector price at ₹600.

Indian left liberals and opposition parties, who have been running a campaign against Indian vaccine makers for last several months, have already slammed Serum Institute, accusing it of setting high prices for state govts and making undue profit out of a pandemic. In light of that situation, it is certain that Bharat Biotech will face even greater opposition, as it has set the prices higher than SII. Moreover, the company already attracted more criticism, as the Congress party and others had alleged that its vaccine is unsafe and not effective.

However, it was expected that Covaxin price will be higher than Covishield, because while SII is making a vaccine developed by Oxford-AstraZeneca, Bharat Biotech developed the Covaxin itself. This means, the company has made huge investments in developing the vaccine, apart from expanding its capacity to produce higher number of doses. The company also had to run an extensive clinical trial program in India to get the vaccine approved. The Covishield main trial was conducted by AstraZeneca, while SII conducted only a small bridge trial in India as required by law.

Along with that, Serum Institute of India enjoys a vast economy of scale, as it is the world’s largest vaccine manufacturer. The company also has a much large order book for Covishield, not only from the Indian government, but also from several foreign nations, and the COVAX, the Covid-19 vaccine initiative by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, and the World Health Organization.

Due to these reasons, SII is able to offer a much cheaper price which Bharat Biotech may not be able to without suffering losses.

Bharat Biotech added in its statement announcing the prices that Covaxin is an inactivated and highly purified vaccine, which makes its manufacturing process expensive due to low yields. It said that all costs towards product development, manufacturing facilities and clinical trials were deployed primarily using internal funding and resources of the company. It said that recovering costs is essential in the journey of innovation towards other vaccines such as Intranasal Covid-19, Chikungunya, Zika, Cholera, and others.

Ayodhra Ram Mandir special coverage by OpIndia

  Support Us  

Whether NDTV or 'The Wire', they never have to worry about funds. In name of saving democracy, they get money from various sources. We need your support to fight them. Please contribute whatever you can afford

OpIndia Staff
OpIndia Staff
Staff reporter at OpIndia

Related Articles

Trending now

Recently Popular

- Advertisement -

Connect with us